MediGene Obtains European Patent on EndoTAG(TM)-1
MediGene AG announced that the US patent office has granted a patent covering the drug candidate EndoTAG(TM)-1. The patent protects the substance EndoTAG(TM)-1 developed by MediGene as a drug for the treatment of various types of cancer.
MediGene has exclusively licensed the patent no. EP 1 210 065 from the University of California, San Francisco. Further patent applications regarding the manufacturing process and administration of the drug have also been filed by MediGene AG. In addition, MediGene holds several patents on the EndoTAG(TM) technology in general.
EndoTAG(TM) aims at a novel method of cancer therapy by "starving out" tumors. EndoTAG(TM)-1 combines the established active substance Paclitaxel with a carrier system of positively charged lipid complexes. They allow a transport of the substance specifically to the negatively charged newly developed tumor blood vessels. There the drug is discharged in order to destroy the blood vessels, thus suppressing the tumor's nutrient supply. MediGene is currently conducting an extensive clinical phase II trial of EndoTAG(TM)-1 for the treatment of pancreatic cancer. Another clinical phase II trial in the indication hormone-resistant breast cancer is about to start in the near future. Apart from that, MediGene is also examining the application of the EndoTAG(TM) technology for the treatment of other diseases.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.